A
Alcista
Alcista · 25%LLY
$1,138.36
Precio del escenario
$1,257.030
+5.405 (+0.43%)Al cierre
Loading chart…
- Máximo
- 1,274.560
- Apertura
- 1,256.000
- Precio medio ponderado por volumen
- 1,260.95
- Volumen
- 2.41M
- Capitalización
- 863.96B
- Mínimo
- 1,251.250
- Importe
- 3.04B
- EV/EBITDA, TTM
- 20.18
Eli Lilly and Company is a medicine company which discovers, develops, manufactures, and markets products in a single business segment called human pharmaceutical products. The Company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. Its Cardiometabolic Health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients. The Company’s products are sold in approximately 90 countries.
Análisis de IA of Eli Lilly and Co (LLY)
ComprarEli Lilly and Co is a good buy right now due to its strong financial performance, with a gross margin of 85.78% in Q2 2026 and a year-to-date price increase of 16.35%. The main risk is the forward P/E ratio of 24.39, which suggests that the stock may be overvalued compared to its earnings growth potential.
Recomendaciones de analistas (22)
Comprar
13 Comprar
8 Mantener
1 Vender
Actual: 1,257.03
Mínimo
950.00
Promedio
—
Máximo
—
BofA
Comprar
—
2026-10-09
BofA
2026-10-09
Precio objetivo
—
Comprar
Cantor Fitzgerald
Sobreponderar
—
2026-10-08
Cantor Fitzgerald
2026-10-08
Precio objetivo
—
Sobreponderar
Morgan Stanley
Sobreponderar
—
2026-10-07
Morgan Stanley
2026-10-07
Precio objetivo
—
Sobreponderar
JPMorgan
Sobreponderar
—
2026-09-28
JPMorgan
2026-09-28
Precio objetivo
—
Sobreponderar
Guggenheim
Comprar
—
2026-09-18
Guggenheim
2026-09-18
Precio objetivo
—
Comprar
Métricas de valoración
El PER previsto actual de Eli Lilly and Co (LLY) es 24.39, frente a su media de 5 años de 40.87.
Escenarios de precio de Alphio AI para LLY
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con LLY en cartera
Cronología de eventos
Noticias
9.010-19PRnewswireLilly Plans to Expand Omvoh Indication for Pediatric Ulcerative Colitis
8.510-18PRnewswireEli Lilly Presents New Drug Data at ESMO Congress
6.510-19FoolBuffett Warns Wall Street of Market Risks
2.010-19stocktwitsSellas Life Sciences Faces Pressure on Regal Trial Results Ahead of ASH
8.510-18FoolViking Therapeutics Raises $575 Million to Fund Trials
Preguntas frecuentes sobre LLY, respondidas por Alphio AI
Eli Lilly and Company is a medicine company which discovers, develops, manufactures, and markets products in a single business segment called human pharmaceutical products. The Company manufactures and distributes its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. Its Cardiometabolic Health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients. The Company’s products are sold in approximately 90 countries. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Eli Lilly and Co is a good buy right now due to its strong financial performance, with a gross margin of 85.78% in Q2 2026 and a year-to-date price increase of 16.35%. The main risk is the forward P/E ratio of 24.39, which suggests that the stock may be overvalued compared to its earnings growth potential.
22 analysts cover LLY: 13 rate it Buy, 8 Hold and 1 Sell. The average price target is 1,192.
Comunidad
Más ↗
💡When Tech & AI sell off, money rotates into other sectors like dividend names, healthcare, etc. Find those rotation setups and look for longs. Learn: - Identify rotation (with heat maps and research) - Look for A+ setups - Trade with cloud and daily breakout - $UNH $LLY live trades Watch now
Mostrar másTrading Rotation Plays: A+ Long Setups | $UNH $LLY $VKTX Watch the video to learn how to trade this repeatable pattern 🎯
Mostrar más
$LLY may be forming a top area. Each time the Cryptic Top Index has issued a red alert before, a pullback followed. Now, that signal has appeared again.
Mostrar más
🚨 $VKTX just took a major step toward bringing its obesity pill to market! Viking Therapeutics has initiated two Phase 3 trials of oral VK2735, targeting patients with obesity both with and without Type 2 diabetes. 📊 Phase 2 results showed up to 12.2% mean weight loss in just 13 weeks, versus 1.3% with placebo. 🔥 The bigger picture? > Injectable VK2735 is already in Phase 3, with enrollment completed in both studies. > Maintenance data showed patients retained 85–90% of prior weight loss with less frequent injections. > Oral maintenance research and VK3019 add further potential to the pipeline. Competition from $LLY and $NVO is heating up, but Viking is expanding its options across oral, injectable and maintenance treatments.
Mostrar más
During market weakness, it's always good to watch which names are still holding up. Right now $LLY fits that description. It's breaking out to the upside and looks like it could drift up to its highs.
Mostrar más
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.